Published on 4 Apr 2024 on Zacks via Yahoo Finance
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
Gritstone Bio GRTS is a clinical-stage biotechnology company focused on developing vaccines targeting multiple indications, including cancer.
In the past week, the company’s stock lost 57.5%. This downside came after management came out with preliminary results from the mid-stage portion of the phase II/III study on its investigational personalized cancer vaccine (PCV), Granite.
The phase II/III study evaluated the combination of Granite as a maintenance therapy in patients with metastatic microsatellite stable colorectal cancer (MSS-CRC).